Vimarsana
Biggest News Aggregation in the World

Page 9 - Executive Pascal Soriot News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Executive Pascal Soriot. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Executive Pascal Soriot Today - Breaking & Trending Today

AstraZeneca reports Covid vaccine sales of $275 mn, expects hit to ease - Vimarsana News

AstraZeneca reports Covid vaccine sales of $275 mn, expects hit to ease

AstraZeneca said its COVID-19 vaccine contributed $275 million to first-quarter sales and shaved three cents per share from its earnings, as it posted better-than-expected results and forecast growth in the second half. This is the first time the Anglo-Swedish drugmaker has given financial details of the distribution and sales of its vaccine, which it developed with Oxford University. It has said it will not make a profit from the shot during the pandemic. Vaccine revenue included delivery of about 68 million doses, AstraZeneca said on Friday, adding that sales in Europe, where it faces a l...

AstraZeneca reports COVID vaccine sales of $275 mln, expects hit to ease - Vimarsana News

AstraZeneca reports COVID vaccine sales of $275 mln, expects hit to ease

ChinaAstraZeneca says on track to deliver on COVID shots as sales hit $275 mln ReutersPushkala AripakaLudwig Burger 5 minute read AstraZeneca said its COVID-19 vaccine sales were $275 million in the first-quarter and it is on track to deliver 200 million doses a month from April, as better-than-expected results and a second half growth forecast boosted its shares. Chief Executive Pascal Soriot again defended the vaccine rollout on Friday, saying that Anglo-Swedish drugmaker had not overpromised on its ability to supply shots, as he defended big cuts in deliveries that prompted a European Unio...

AstraZeneca says on track to deliver on COVID shots as sales hit $275 million - Vimarsana News

AstraZeneca says on track to deliver on COVID shots as sales hit $275 million

AstraZeneca says on track to deliver on COVID shots as sales hit $275 million By Pushkala Aripaka and Ludwig Burger Reuters (Reuters) -AstraZeneca said its COVID-19 vaccine sales were $275 million in the first-quarter and it is on track to deliver 200 million doses a month from April, as better-than-expected results and a second half growth forecast boosted its shares. Chief Executive Pascal Soriot again defended the vaccine rollout on Friday, saying that Anglo-Swedish drugmaker had not overpromised on its ability to supply shots, as he defended big cuts in deliveries that prompted a European...

AstraZeneca says on track to deliver on Covid shots as sales hit $275 mln - Vimarsana News

AstraZeneca says on track to deliver on Covid shots as sales hit $275 mln

boosted its shares. Chief Executive Pascal Soriot again defended the vaccine rollout on Friday, saying that Anglo-Swedish drugmaker had not overpromised on its ability to supply shots, as he defended big cuts in deliveries that prompted a European Union lawsuit. AstraZeneca, which has said it will not make a profit from the shot during the pandemic, was reporting financial details of distribution and sales of the vaccine it developed with Oxford University for the first time. It said the revenue included delivery of about 68 million doses, adding that European sales were $224 million, emer...

AstraZeneca forecast boosts shares as COVID shot sales hit $275m - Vimarsana News

AstraZeneca forecast boosts shares as COVID shot sales hit $275m

  >>  Reuters Published: 30 Apr 2021 03:07 PM BdST Updated: 30 Apr 2021 04:26 PM BdST The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, US, March 22, 2021. REUTERS AstraZeneca said its COVID-19 vaccine sales were $275 million in the first-quarter and it is on track to deliver 200 million doses a month from April, as better-than-expected results and a second half growth forecast boosted its shares. "); } Chief Executive Pascal Soriot again defended the vaccine rollout on Friday, saying that Anglo-Swedish drugmaker had not overpromised on its...